ESC HF 2021: β-blockers Withdrawal in Patients With HFpEF & Chronotropic Incompetence

Подробнее о видео

In this video interview from ESC's 2021 Heart Failure Congress, Dr Julio Nunez Villota (University of Valencia, Valencia, ES) discusses the findings of the Preserve-HR trial. This was a randomised single-center study that aimed to find the effect of beta-blocker withdrawal in patients with HFpEF and chronotropic incompetence.

Questions:

1. Could you briefly remind us of the trial's main aims, design and endpoints?
2. What were the key findings of the Preserve-HR Trial?
3. How should these findings impact practice? What are the next steps?

Editor: Jordan Rance

Filmed Remotely from Valencia, 2021.

Radcliffe Group is a specialist provider of Cardiovascular, Renal and Metabolic (CVRM) content, The Radcliffe Group offers physicians access to content through a variety of media formats stemming from industry-leading peer-reviewed research journals, video interviews, live events and online medical courses.